MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Total Inventories 2011-2026 | ALNY
Annual Total Inventories Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.7 M | 78.5 M | 89.1 M | 129 M | 86.4 M | 75.2 M | 56.3 M | 24.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 129 M | 24.1 M | 77.7 M |
Quarterly Total Inventories Alnylam Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.7 M | 65.6 M | 78.5 M | 76 M | 84 M | 94 M | 89.1 M | 95.8 M | 100 M | 132 M | 129 M | 115 M | - | 78.5 M | 86.4 M | 97.9 M | 84.4 M | 73.9 M | 75.2 M | 75.2 M | 75.2 M | 75.2 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 24.1 M | 24.1 M | 24.1 M | 24.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 24.1 M | 75 M |
Total Inventories of other stocks in the Biotechnology industry
| Issuer | Total Inventories | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Xeris Pharmaceuticals
XERS
|
68.7 M | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
UroGen Pharma Ltd.
URGN
|
16.5 M | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
6.92 M | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
GT Biopharma
GTBP
|
42 K | $ 0.47 | -2.41 % | $ 892 K | USA |
 |
AbCellera Biologics
ABCL
|
6.34 M | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
16.2 M | - | -24.86 % | $ 820 K | USA |
 |
Agenus
AGEN
|
55.5 K | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
32.9 M | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Albireo Pharma
ALBO
|
194 K | - | -0.23 % | $ 916 M | USA |
 |
Amarin Corporation plc
AMRN
|
196 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
4.95 B | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
13.6 M | - | - | $ 8.14 B | USA |
 |
Aptorum Group Limited
APM
|
39.1 K | $ 0.83 | 5.37 % | $ 4.53 M |  China |
 |
Apellis Pharmaceuticals
APLS
|
143 M | $ 20.67 | -1.38 % | $ 2.61 B | USA |